{"url":"https://newsforagent.com/news/2026-10-19/nouscom-series-d-cancer-interception","markdown_url":"https://newsforagent.com/news/2026-10-19/nouscom-series-d-cancer-interception.md","title":"Nouscom Raises €120 Million Series D Led by M Ventures","headline":"Nouscom Closes Oversubscribed €120 Million Series D to Fund Lynch Syndrome Cancer Trial","description":"Nouscom closed an oversubscribed €120 million Series D led by M Ventures and Revelation Partners to fund a registration-enabling NOUS-209 trial in Lynch Syndrome.","section":"Funding","published_at":"2026-10-19T06:42:21+00:00","modified_at":"2026-10-19T06:42:21+00:00","author":"News Desk","key_takeaways":["Nouscom closed an oversubscribed €120 million ($135 million) Series D co-led by M Ventures and Revelation Partners.","New investors Angelini Industries, the European Investment Bank and Neva SGR joined, with all existing investors participating.","Proceeds fund a global registration-enabling trial of NOUS-209 in Lynch Syndrome carriers, with long-term data to be presented at ESMO on October 25, 2026."],"companies":[{"name":"Nouscom","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00041sk/nouscom","website":"https://nouscom.com"},{"name":"M Ventures","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0004dxf/m-ventures","website":"https://www.m-ventures.com"},{"name":"5AM Ventures","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00003bz/5am-ventures","website":"http://www.5amventures.com"}],"source":{"publisher":"GlobeNewswire","title":"Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO","url":"https://www.globenewswire.com/news-release/2026/10/19/3382989/0/en/nouscom-raises-120-million-135-million-in-oversubscribed-series-d-financing-and-will-present-long-term-cancer-interception-clinical-data-in-lynch-syndrome-carriers-at-esmo.html"},"other_sources":[],"tags":["Funding","Nouscom","M Ventures","5AM Ventures"],"body_markdown":"[Nouscom](https://akta.pro/company-profiles/00041sk/nouscom) closed an oversubscribed €120 million ($135 million) Series D financing co-led by [M Ventures](https://akta.pro/company-profiles/0004dxf/m-ventures) and Revelation Partners, the clinical-stage cancer interception biotech said on October 19, 2026. The Basel, Switzerland-based company said new investors Angelini Industries, the European Investment Bank and Neva SGR joined the round, with participation from all existing investors. The announcement was distributed by [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/19/3382989/0/en/nouscom-raises-120-million-135-million-in-oversubscribed-series-d-financing-and-will-present-long-term-cancer-interception-clinical-data-in-lynch-syndrome-carriers-at-esmo.html).\n\n## Nouscom's Series D and the NOUS-209 Trial\n\nNouscom said proceeds will fund advancement of its lead asset NOUS-209, an investigational off-the-shelf neoantigen-based cancer immunotherapy, through a single global registration-enabling clinical trial for cancer interception in Lynch Syndrome carriers. The FDA has granted NOUS-209 Fast Track designation for that use.\n\nThe financing coincides with a presentation of long-term cancer interception data from a Phase 1b/2 trial of NOUS-209 in Lynch Syndrome carriers at the European Society of Medical Oncology Congress in Madrid, Spain, on October 23-27, 2026. Eduardo Vilar-Sanchez, chair ad interim of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center, will present the data on October 25, 2026.\n\nThe abstract published by ESMO reports that all evaluable Lynch Syndrome carriers dosed with NOUS-209 remained free of advanced adenomas and colorectal cancer, as determined by colonoscopy, after years 1 and 2 (n=43; n=17, respectively). The company said the data were strengthened by anti-neoantigen T-cell responses that were further enhanced following annual re-treatment.\n\n\"Over two million LS carriers live with up to an 80% lifetime cancer risk and nothing to offer them but surveillance and surgery,\" said Marina Udier, Chief Executive Officer of Nouscom. \"This financing, alongside the data we are presenting at ESMO, puts us closer to a world where cancer is stopped before it starts.\"\n\nGöran Ando, Independent Chair of the Board of Nouscom, said the financing reflects investor confidence in the company's vision and the potential of cancer interception. Hakan Goker, Managing Director and Head of Biotechnology Investments at M Ventures, said the company's cancer interception approach and platform set it apart.\n\n## Nouscom's Funding History\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Nouscom's Series C extension in March 2024 was €75.8 million, and the company has raised €129.8 million across three funding rounds. The same records list a Series C of $73.4 million in November 2023 led by Bpifrance, Andera Partners and M Ventures, a Series B of $48.8 million in November 2017 led by Abingworth, and a Series A of $13.6 million in May 2016 led by EQT Life Sciences.\n\n| Round | Date | Amount | Lead |\n| --- | --- | --- | --- |\n| Series A | May 2016 | $13.6 million | EQT Life Sciences |\n| Series B | November 2017 | $48.8 million | Abingworth |\n| Series C | November 2023 | $73.4 million | Bpifrance, Andera Partners, M Ventures |\n| Series C extension | March 2024 | €75.8 million | Angelini Ventures |\n\n## ESMO Presentation Details\n\nThe ESMO abstract, number 3438O, is titled \"Safety and Immunogenicity of Re-vaccination with Nous-209: a neoantigen vaccine for cancer interception in Lynch syndrome carriers.\" The presentation is scheduled for October 25, 2026, at 15:15 hrs CEST in the Granada Auditorium, Hall 4.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}